LGND · Ligand Pharmaceuticals Inc · Share Buybacks
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Equity Offering (ATM) Programs
| Program Established | Last Amended | Capacity | Remaining | Runs Through | Source |
|---|---|---|---|---|---|
| 2022-09-30 | — | $100,000,000 | — | — | 10-Q , filed 2025-08-08 |
Cash spent on buybacks by quarter
Cash deployed each quarter, with the average price paid where the company reported it (on today's share basis). Δ marks quarters derived from the company's cumulative year-to-date disclosures.
Repurchase History
| Fiscal Year Ended | Cash Spent | Source |
|---|---|---|
| 2026-09-30 YTD | $60,000,000 | 10-Q, filed 2026-10-30 |
| 2025-12-31 | $15,000,000 | 10-K, filed 2026-02-27 |
| 2024-12-31 | $0 | 10-K, filed 2026-02-27 |
| 2023-12-31 | $0 | 10-K, filed 2026-02-27 |
| 2022-12-31 | $0 | 10-K, filed 2023-02-28 |
| 2021-12-31 | $0 | 10-K, filed 2023-02-28 |
| 2020-12-31 | $77,998,000 | 10-K, filed 2023-02-28 |
| 2019-12-31 | $453,048,000 | 10-K, filed 2022-02-28 |
| 2018-12-31 | $122,868,000 | 10-K, filed 2021-02-24 |
| 2017-12-31 | $1,966,000 | 10-K, filed 2020-02-27 |
| 2016-12-31 | $3,901,000 | 10-K, filed 2019-02-28 |
| 2015-12-31 | $489,000 | 10-K, filed 2018-03-01 |
| 2014-12-31 | $67,954,000 | 10-K, filed 2017-02-28 |
| 2013-12-31 | $0 | 10-K, filed 2016-11-14 |
| 2012-12-31 | $0 | 10-K, filed 2015-02-23 |
| 2011-12-31 | $55,000 | 10-K/A, filed 2014-12-12 |
| 2010-12-31 | $91,000 | 10-K, filed 2013-03-14 |
Share counts and average prices are restated onto today's share basis across later stock splits; cash spent is as reported. ‡ marks a row kept as filed because a later split could not be attributed to this stock's shares.